• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两价重组水疱性口炎病毒疫苗在致死性埃博拉病毒感染叙利亚仓鼠模型中的保护效力。

Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.

机构信息

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.

出版信息

J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1090-7. doi: 10.1093/infdis/jir379.

DOI:10.1093/infdis/jir379
PMID:21987746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3189997/
Abstract

BACKGROUND

Outbreaks of filoviral hemorrhagic fever occur sporadically and unpredictably across wide regions in central Africa and overlap with the occurrence of other infectious diseases of public health importance.

METHODS

As a proof of concept we developed a bivalent recombinant vaccine based on vesicular stomatitis virus (VSV) expressing the Zaire ebolavirus (ZEBOV) and Andes virus (ANDV) glycoproteins (VSVΔG/Dual) and evaluated its protective efficacy in the common lethal Syrian hamster model. Hamsters were vaccinated with VSVΔG/Dual and were lethally challenged with ZEBOV or ANDV. Time to immunity and postexposure treatment were evaluated by immunizing hamsters at different times prior to and post ZEBOV challenge.

RESULTS

A single immunization with VSVΔG/Dual conferred complete and sterile protection against lethal ZEBOV and ANDV challenge. Complete protection was achieved with an immunization as close as 3 days prior to ZEBOV challenge, and 40% of the animals were even protected when treated with VSVΔG/Dual one day postchallenge. In comparison to the monovalent VSV vaccine, the bivalent vaccine has slightly reduced postexposure efficacy most likely due to its restricted lymphoid organ replication.

CONCLUSIONS

Bivalent VSV vectors are a feasible approach to vaccination against multiple pathogens.

摘要

背景

丝状病毒出血热的爆发零星且不可预测地发生在中非的广大地区,与其他具有公共卫生重要性的传染病同时发生。

方法

作为概念验证,我们开发了一种基于水疱性口炎病毒(VSV)的二价重组疫苗,该疫苗表达扎伊尔埃博拉病毒(ZEBOV)和安第斯病毒(ANDV)糖蛋白(VSVΔG/Dual),并在常见的致命叙利亚仓鼠模型中评估其保护效力。仓鼠用 VSVΔG/Dual 疫苗接种,并接受 ZEBOV 或 ANDV 的致死性攻击。通过在 ZEBOV 攻击之前和之后的不同时间点免疫仓鼠来评估免疫时间和暴露后治疗。

结果

单次免疫 VSVΔG/Dual 可完全、无菌地预防致命的 ZEBOV 和 ANDV 攻击。在 ZEBOV 攻击前 3 天进行免疫即可实现完全保护,而在攻击后一天用 VSVΔG/Dual 治疗时,有 40%的动物甚至得到了保护。与单价 VSV 疫苗相比,二价疫苗的暴露后疗效略有降低,这可能是由于其限制了淋巴器官的复制。

结论

双价 VSV 载体是针对多种病原体进行疫苗接种的可行方法。

相似文献

1
Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.两价重组水疱性口炎病毒疫苗在致死性埃博拉病毒感染叙利亚仓鼠模型中的保护效力。
J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1090-7. doi: 10.1093/infdis/jir379.
2
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.针刺伤后使用水疱性口炎病毒载体埃博拉疫苗进行紧急暴露后接种。
JAMA. 2015;313(12):1249-55. doi: 10.1001/jama.2015.1995.
3
Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.基于水疱性口炎病毒的疫苗可保护仓鼠免受安第斯病毒的致死性攻击。
J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.
4
Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters.双价 VSV 载体介导仓鼠对安第斯病毒挑战的快速和有效保护。
Viruses. 2024 Feb 11;16(2):279. doi: 10.3390/v16020279.
5
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.基于水疱性口炎病毒的疫苗可保护非人灵长类动物免受本迪布焦埃博拉病毒感染。
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.
6
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.单次注射疫苗可保护非人灵长类动物免受马尔堡病毒和三种埃博拉病毒的感染。
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
7
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.基于水疱性口炎病毒的埃博拉疫苗,具有提高的交叉保护效力。
J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1066-74. doi: 10.1093/infdis/jir348.
8
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).接种基于重组水疱性口炎病毒的埃博拉疫苗(rVSVΔG-ZEBOV-GP)后对扎伊尔埃博拉糖蛋白和病毒载体蛋白的细胞和体液免疫。
Vaccine. 2023 Feb 17;41(8):1513-1523. doi: 10.1016/j.vaccine.2023.01.059. Epub 2023 Jan 31.
9
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.埃博拉病毒糖蛋白 Fc 融合蛋白赋予接种疫苗的小鼠免受致死性挑战的保护。
Vaccine. 2011 Apr 5;29(16):2968-77. doi: 10.1016/j.vaccine.2011.01.113. Epub 2011 Feb 15.
10
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.高剂量水疱性口炎病毒载体埃博拉病毒疫苗可引起猪的水疱病,但不会发生水平传播。
Emerg Microbes Infect. 2021 Dec;10(1):651-663. doi: 10.1080/22221751.2021.1903343.

引用本文的文献

1
Mapping of susceptibility loci for Ebola virus pathogenesis in mice.小鼠埃博拉病毒发病机制易感性基因座的定位。
Cell Rep. 2024 May 28;43(5):114127. doi: 10.1016/j.celrep.2024.114127. Epub 2024 Apr 21.
2
Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters.双价 VSV 载体介导仓鼠对安第斯病毒挑战的快速和有效保护。
Viruses. 2024 Feb 11;16(2):279. doi: 10.3390/v16020279.
3
Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates.单次剂量基于水疱性口炎病毒的疫苗可预防非人灵长类动物感染基孔肯雅热。
Sci Adv. 2023 Sep 8;9(36):eadj1428. doi: 10.1126/sciadv.adj1428. Epub 2023 Sep 6.
4
Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.VSV-EBOV 对感染埃博拉病毒的恒河猴的接触后预防效果有限。
J Infect Dis. 2023 Nov 13;228(Suppl 7):S721-S729. doi: 10.1093/infdis/jiad280.
5
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.病毒载体疫苗:在人类疾病中的设计、开发、预防和治疗应用。
Signal Transduct Target Ther. 2023 Apr 7;8(1):149. doi: 10.1038/s41392-023-01408-5.
6
Replicating-Competent VSV-Vectored Pseudotyped Viruses.复制型 VSV 载体假型病毒。
Adv Exp Med Biol. 2023;1407:329-348. doi: 10.1007/978-981-99-0113-5_18.
7
Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins.用表达刺突和核衣壳蛋白的基于 VSV 的疫苗预防 COVID-19。
Front Immunol. 2022 Oct 24;13:1025500. doi: 10.3389/fimmu.2022.1025500. eCollection 2022.
8
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Vaccine to Inform Marburg Virus and Vaccines.从研发和推广重组水疱性口炎病毒载体埃博拉病毒糖蛋白疫苗(rVSVΔG-ZEBOV-GP)中吸取的经验教训,为马尔堡病毒及疫苗提供参考。
Vaccines (Basel). 2022 Sep 1;10(9):1446. doi: 10.3390/vaccines10091446.
9
A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.一种基于重组水疱性口炎病毒的二价疫苗能有效预防 SARS-CoV-2 和甲型流感病毒感染。
J Virol. 2022 Sep 28;96(18):e0133722. doi: 10.1128/jvi.01337-22. Epub 2022 Sep 7.
10
A platform technology for generating subunit vaccines against diverse viral pathogens.一种针对多种病毒病原体的亚单位疫苗的生成平台技术。
Front Immunol. 2022 Aug 18;13:963023. doi: 10.3389/fimmu.2022.963023. eCollection 2022.

本文引用的文献

1
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.基于重组水疱性口炎病毒的埃博拉和马尔堡病毒感染疫苗。
J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1075-81. doi: 10.1093/infdis/jir349.
2
Progress in filovirus vaccine development: evaluating the potential for clinical use.丝状病毒疫苗研发进展:评估临床应用潜力。
Expert Rev Vaccines. 2011 Jan;10(1):63-77. doi: 10.1586/erv.10.152.
3
Ebola haemorrhagic fever.埃博拉出血热。
Lancet. 2011 Mar 5;377(9768):849-62. doi: 10.1016/S0140-6736(10)60667-8.
4
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies.用于检测丝状病毒属特异性抗体的酶联免疫吸附测定。
Clin Vaccine Immunol. 2010 Nov;17(11):1723-8. doi: 10.1128/CVI.00170-10. Epub 2010 Sep 22.
5
Recent advances in Ebolavirus vaccine development.埃博拉病毒疫苗研发的最新进展。
Hum Vaccin. 2010 Jun;6(6):439-49. doi: 10.4161/hv.6.6.11097. Epub 2010 Jun 1.
6
Prospects for immunisation against Marburg and Ebola viruses.针对马尔堡病毒和埃博拉病毒的免疫前景。
Rev Med Virol. 2010 Nov;20(6):344-57. doi: 10.1002/rmv.661.
7
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.用单一复合型腺病毒载体保护非人灵长类动物免受两种埃博拉病毒感染。
Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.
8
Hantavirus pulmonary syndrome.汉坦病毒肺综合征。
Infect Dis Clin North Am. 2010 Mar;24(1):159-73. doi: 10.1016/j.idc.2009.10.011.
9
Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.表达汉坦病毒蛋白的腺病毒载体可保护仓鼠免受安第斯病毒的致死性攻击。
J Virol. 2009 Jul;83(14):7285-95. doi: 10.1128/JVI.00373-09. Epub 2009 Apr 29.
10
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.单次注射疫苗可保护非人灵长类动物免受马尔堡病毒和三种埃博拉病毒的感染。
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.